A Phase I/II Study of TJ004309 for Advanced Solid Tumor

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

May 9, 2020

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

TJ004309

Antibody to CD73

DRUG

Toripalimab

Humanized monoclonal antibody to PD-1

Trial Locations (23)

130021

The First Bethune Hospital of Jilin University, Changchun

200032

Fudan University Shanghai Cancer Center, Shanghai

510080

Guangdong Provincial People's Hospital, Guangzhou

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Army Medical Center of PLA, Chongqing

Chongqing Cancer Hospital, Chongqing

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou

Cancer Hospital affiliated to Shantou University Medical College, Shantou

The First Affiliated Hospital of Guangxi Medical University, Nanning

Harbin Medical University Cancer Hospital, Haerbin

Henan Cancer Hospital, Zhengzhou

Hubei Cancer Hospital, Wuhan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Hunan Cancer Hospital, Changsha

Northern Jiangsu People's Hospital, Yangzhou

The Second Affiliated Hospital of Nanchang University, Nanchang

Liaoning Cancer Hospital and Institute, Shenyang

The First Hospital of China Medical University, Shenyang

The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an

Sichuan Cancer Hospital, Chengdu

Yunnan Cancer Hospital, Kunming

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hanzhou

All Listed Sponsors
lead

TJ Biopharma Co., Ltd.

INDUSTRY